Misonix BoneScalpel™ Reported to Save Blood Loss in Spinal Fusions with Similar Diagnosis - NewsOn6.com - Tulsa, OK - News, Weather, Video and Sports - KOTV.com |

Misonix BoneScalpel™ Reported to Save Blood Loss in Spinal Fusions with Similar Diagnosis

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Misonix, Inc.

FARMINGDALE, N.Y., July 15, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced that a team of spine surgeons from Rady Children's Hospital in San Diego, CA has published their findings from a recent study on utilization of the ultrasonic BoneScalpel in spinal fusion surgery. The article "Blood loss reduction during surgical correction of adolescent idiopathic scoliosis utilizing an ultrasonic BoneScalpel" is published in the July edition of Spinal Deformity, which is the official journal of the Scoliosis Research Society.

The retrospective review of prospectively collected data compared data from 20 consecutive patients with adolescent idiopathic scoliosis who underwent posterior spinal fusion using the ultrasonic BoneScalpel by a single surgeon with two control groups: 1.) the 20 most recent prior cases of the same surgeon before beginning use of the BoneScalpel and 2.) 20 cases of the same surgeon before using the BoneScalpel and matched based on Cobb angle magnitudes, a measure for surgical correction of spinal deformity. The authors concluded that use of the ultrasonic BoneScalpel to perform the bone cuts associated with facetectomies and apical Ponte-type posterior releases resulted in significantly less bleeding compared with cuts made with standard osteotomes and rongeurs, limiting overall blood loss by 30 to 40%.

Dr. Peter Newton, senior author of the article comments: "Previous articles have reported that the BoneScalpel is safe and effective in performing a variety of spine surgeries and an observed decrease in intraoperative bleeding had been noted by other authors. We felt it important to conduct an empirical evaluation of the blood loss by looking at a single diagnosis - adolescent idiopathic scoliosis, with two control groups by a single surgeon. Our results showed a substantial reduction in blood loss from cuts on spinal bone which led to an equally significant reduction in transfused cell saver blood in this scoliosis patient population."

Blood loss varies greatly in spine surgery and is typically higher in spinal fusions. Greater blood loss is associated with more blood transfusion and thus exposure to blood products and higher risk of disease transmission or adverse reactions or prolonged stay in the hospital. Blood products like intraoperative cell savers also come at a considerable logistics and economic burden to the hospital.

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix adds, "We are extremely pleased by the continuing and expanding evidence on BoneScalpel's unique benefits and its increasing utilization in advanced spine surgeries around the world. The observed reduction in blood loss in these young patients with severe spinal deformities is clearly remarkable and has been confirmed by other top hospitals in the U.S. and overseas. Hospitals are increasingly trying to reduce the amount of blood transfusions and it is important to see that the BoneScalpel can contribute to these efforts, both from a clinical and economic perspective."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact:

Investor Contact:

Richard Zaremba

Joe Diaz

631-694-9555

Lytham Partners

invest@misonix.com

602-889-9700


info@misonix.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
News On 6
303 N. Boston Ave.
Tulsa, OK 74103
TULSA'S OWN TM
GREEN COUNTRY'S OWN TM
Oklahoma's Own Newson6.com is proud to provide Oklahomans with timely and relevant news and information, sharing the stories, pictures and loves of Oklahomans across our great state including Tulsa's Own and Green Country's Own.
All content © Copyright 2000 - 2014, WorldNow and KOTV. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.